ATE421584T1 - Cpg rezeptor (cpg-r) und darauf bezogene methoden - Google Patents

Cpg rezeptor (cpg-r) und darauf bezogene methoden

Info

Publication number: ATE421584T1
Authority: AT; Austria
Prior art keywords: cpg; receptor; related methods; methods; bind
Prior art date: 1999-11-02

Application number

AT00989738T

Other languages

English (en)

Inventor

Mary Mackichan

Original Assignee

Novartis Vaccines & Diagnostic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-02

Filing date

2000-11-01

Publication date

2009-02-15

2000-11-01 Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic

2009-02-15 Application granted granted Critical

2009-02-15 Publication of ATE421584T1 publication Critical patent/ATE421584T1/de

Links

102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 abstract 1
108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT00989738T 1999-11-02 2000-11-01 Cpg rezeptor (cpg-r) und darauf bezogene methoden ATE421584T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16315799P	1999-11-02	1999-11-02
US16738999P	1999-11-24	1999-11-24

Publications (1)

Publication Number	Publication Date
ATE421584T1 true ATE421584T1 (de)	2009-02-15

Family

ID=26859391

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00989738T ATE421584T1 (de)	1999-11-02	2000-11-01	Cpg rezeptor (cpg-r) und darauf bezogene methoden

Country Status (8)

Country	Link
US (2)	US20060121529A1 (de)
EP (2)	EP1226252A2 (de)
JP (3)	JP2003514791A (de)
AT (1)	ATE421584T1 (de)
CA (2)	CA2389765A1 (de)
DE (1)	DE60041452D1 (de)
ES (1)	ES2319858T3 (de)
WO (2)	WO2001036641A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
JP2005500806A (ja)	2000-09-15	2005-01-13	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
WO2003078595A2 (en) *	2002-03-15	2003-09-25	Astral, Inc.	Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
EP2258712A3 (de) *	2002-03-15	2011-05-04	Multicell Immunotherapeutics, Inc.	Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
EP3006043B1 (de)	2002-04-04	2019-05-29	Zoetis Belgium S.A.	Immunostimulatorische g,u-haltige oligoribonucleotide
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
DE10233994A1 (de) *	2002-07-25	2004-02-12	Phenion Gmbh & Co. Kg	Kosmetische oder pharmazeutische Zubereitungen enthaltend Nukleinsäuren auf der Basis nicht-methylierter CpG-Motive
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003291755A1 (en)	2002-11-05	2004-06-07	Isis Pharmaceuticals, Inc.	Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
WO2004041889A2 (en)	2002-11-05	2004-05-21	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
CA2504720C (en)	2002-11-05	2013-12-24	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
JP4579911B2 (ja)	2003-06-03	2010-11-10	アイシス・ファーマシューティカルズ・インコーポレイテッド	スルビビン発現の調節
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
JP4538522B2 (ja)	2005-11-25	2010-09-08	コーリーファーマシューティカルゲーエムベーハー	免疫刺激性オリゴリボヌクレオチド
DE102006031483B4 (de) *	2006-07-07	2009-12-24	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Zellulärer Pyrogentest
RU2487716C2 (ru)	2007-10-03	2013-07-20	Кварк Фармасьютикалс, Инк.	Новые структуры малых интерферирующих рнк (sirna)
WO2009147684A2 (en)	2008-06-06	2009-12-10	Quark Pharmaceuticals, Inc.	Compositions and methods for treatment of ear disorders
WO2010080452A2 (en)	2008-12-18	2010-07-15	Quark Pharmaceuticals, Inc.	siRNA COMPOUNDS AND METHODS OF USE THEREOF
AU2010324658A1 (en)	2009-11-26	2012-05-03	Quark Pharmaceuticals, Inc.	siRNA compounds comprising terminal substitutions
EP2862929B1 (de)	2009-12-09	2017-09-06	Quark Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Behandlung von Erkrankungen, Störungen oder Läsionen des ZNS
WO2011084193A1 (en)	2010-01-07	2011-07-14	Quark Pharmaceuticals, Inc.	Oligonucleotide compounds comprising non-nucleotide overhangs
CA2828544A1 (en)	2011-03-03	2012-09-07	Quark Pharmaceuticals, Inc.	Oligonucleotide modulators of the toll-like receptor pathway
US9796979B2 (en)	2011-03-03	2017-10-24	Quark Pharmaceuticals Inc.	Oligonucleotide modulators of the toll-like receptor pathway
US20140323549A1 (en)	2011-11-08	2014-10-30	Quark Pharmaceuticals, Inc.	Methods and compositions for treating diseases, disorders or injury of the nervous system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2331622T3 (es) *	1997-05-07	2010-01-11	Schering Corporation	Proteinas receptoras humanas similares a toll, reactivos y metodos relacionados.
EP1003531B1 (de) *	1997-05-20	2007-08-22	Ottawa Health Research Institute	Verfahren zur Herstellung von Nukleinsäurekonstrukten
AUPP728898A0 (en) *	1998-11-25	1998-12-17	University Of Queensland, The	Immunostimulatory dna

2000
- 2000-11-01 WO PCT/US2000/041726 patent/WO2001036641A2/en not_active Ceased
- 2000-11-01 JP JP2001538520A patent/JP2003514791A/ja not_active Withdrawn
- 2000-11-01 EP EP00993110A patent/EP1226252A2/de not_active Ceased
- 2000-11-01 WO PCT/US2000/041735 patent/WO2001032877A2/en not_active Ceased
- 2000-11-01 EP EP00989738A patent/EP1226251B1/de not_active Expired - Lifetime
- 2000-11-01 DE DE60041452T patent/DE60041452D1/de not_active Expired - Lifetime
- 2000-11-01 ES ES00989738T patent/ES2319858T3/es not_active Expired - Lifetime
- 2000-11-01 CA CA002389765A patent/CA2389765A1/en not_active Abandoned
- 2000-11-01 CA CA002390031A patent/CA2390031A1/en not_active Abandoned
- 2000-11-01 AT AT00989738T patent/ATE421584T1/de active
- 2000-11-01 JP JP2001535559A patent/JP4566494B2/ja not_active Expired - Fee Related
2006
- 2006-02-08 US US11/350,153 patent/US20060121529A1/en not_active Abandoned
2010
- 2010-06-17 JP JP2010138789A patent/JP2010263900A/ja not_active Withdrawn
2011
- 2011-02-22 US US13/031,858 patent/US20110306040A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2001036641A3 (en)	2001-11-01
CA2389765A1 (en)	2001-05-10
WO2001032877A2 (en)	2001-05-10
EP1226252A2 (de)	2002-07-31
JP2003514791A (ja)	2003-04-22
JP4566494B2 (ja)	2010-10-20
EP1226251A2 (de)	2002-07-31
WO2001036641A2 (en)	2001-05-25
EP1226251B1 (de)	2009-01-21
DE60041452D1 (de)	2009-03-12
ES2319858T3 (es)	2009-05-14
US20110306040A1 (en)	2011-12-15
JP2010263900A (ja)	2010-11-25
WO2001032877A3 (en)	2002-01-03
WO2001032877A9 (en)	2002-08-15
CA2390031A1 (en)	2001-05-25
US20060121529A1 (en)	2006-06-08
JP2003514219A (ja)	2003-04-15

Legal Events

Date

Code

Title

Description

2009-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1226251

Country of ref document: EP

Publication	Publication Date	Title
ATE421584T1 (de)	2009-02-15	Cpg rezeptor (cpg-r) und darauf bezogene methoden
CY1112101T1 (el)	2015-11-04	Νευροτροφικοι παραγοντες
BR0011849A (pt)	2003-05-27	Anticorpos enxertados lm609 melhorados
AU7301898A (en)	1998-06-10	Survivin, a protein that inhibits cellular apoptosis, and its modulation
CY1111278T1 (el)	2015-08-05	Συστημα ασφαλειας
DE69835143D1 (de)	2006-08-17	Selektion von proteinen mittels rns-protein fusionen
DK0593618T3 (da)	1998-11-23	Screeningsassay til påvisning af DNA-bindende molekyler
ATE313625T1 (de)	2006-01-15	ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN
AU3143897A (en)	1997-12-09	Oligonucleotides which specifically bind retroviral nucleocapsid proteins
ATE468533T1 (de)	2010-06-15	Enzym-protein-komplex
DE50111331D1 (de)	2006-12-07	Neue verwendung von proteinhydrolysaten
ATE350472T1 (de)	2007-01-15	Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
DK1082423T3 (da)	2006-02-13	Cyclin E2-gener og -proteiner
DE60025704D1 (de)	2006-04-13	Das goodpasture-antigen bindende protein
BR9710919A (pt)	1999-08-17	Proteina purificada sr-p70
DE60031965D1 (de)	2007-01-04	Hochsensitiver nachweis von biomolekülen mittels "phage display"
ATE412067T1 (de)	2008-11-15	Polypeptide mit spezieller, funktioneller domäne, verfahren zu ihrer identifikation und anwendungen derselben
ATE219515T1 (de)	2002-07-15	Methoden und reagenzien zur regulierung von apoptosis
DE69836485D1 (de)	2007-01-04	Hepatitis e-virus aus dem schwein und dessen verwendungen
DE59813125D1 (de)	2006-03-02	Srcr domäne-enthaltendes protein
WO2003004678A3 (en)	2004-04-01	Novel receptors
SE0100412D0 (sv)	2001-02-09	Novel human poly(A) polymerase
SE0002364D0 (sv)	2000-06-22	Growth Factors
DE602004027000D1 (de)	2010-06-17	Verfahren zur Identifizierung aktivierter Polymer-Komplexe zur sekundären Stellen-spezifischen Modifikation von Protein Ziel-Gruppen.
ATE369381T1 (de)	2007-08-15	NUKLEARES PROTEIN ßSHOCAß - EINE KOMPONENTE DES WNT SIGNALTRANSDUKTIONSWEGES